THE ROLE OF THE PHARMACIST IN THE DRUG MANAGEMENT OF PREECLAMPSIA: PROTOCOLS, SAFETY, AND EFFECTIVENESS

Abstract

Introduction: Preeclampsia is one of the main hypertensive syndromes of pregnancy, associated with maternal and perinatal risks. Proper drug management is essential to prevent complications, with the pharmacist playing a key role in ensuring therapeutic safety and effectiveness. Objective: To analyze drug management protocols, safety measures, and the effectiveness of pharmaceutical interventions in preeclampsia. Methodology: An integrative literature review was conducted, with searches between 2018 and 2024 in SciELO, PubMed, and Google Scholar. Studies in Portuguese and English addressing pharmaceutical practice, therapeutic protocols, and medication safety in pregnant women were included. Discussion and Results: Evidence shows that pharmacist involvement improves adherence, reduces failures, and prevents adverse events. National and international protocols, such as those from RBEHG, ACOG, and NICE, recommend magnesium sulfate, methyldopa, hydralazine, and labetalol, with the pharmacist responsible for adapting therapy to patient and institutional needs. Quality indicators, including blood pressure control, reduction of complications, and maternal satisfaction, highlight the benefits of pharmaceutical care. Conclusion: Integrating pharmacists into multidisciplinary teams is strategic to promote rational drug use, enhance clinical safety, and improve maternal and neonatal outcomes.